This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ARIAD Announces Ponatinib Presentations At Annual American Society Of Hematology Meeting

Stocks in this article: ARIA

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.

PACE Trial: 12-Month Follow Up in Chronic Phase Patients

 
Title:   A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Oral Session: 632. Chronic Myeloid Leukemia - Therapy I Session
Date & Time: Sunday, December 9, 2012, 4:30 p.m.
Abstract No.: 163
Presenter:

Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center)

Location: Georgia World Congress Center, A411-A412
 

PACE Trial: Efficacy and Safety in Advanced Phase Patients

 
Title: Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Oral Session: 632. Chronic Myeloid Leukemia - Therapy II Session
Date and Time: Tuesday, December 11, 2012 at 8:00 a.m.
Abstract No.: 915
Presenter: Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center)
Location: Georgia World Congress Center, A411-A412
 

PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy

 
Title: Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP‐CML): Results from the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3749
Presenter: Dong-Wook Kim, M.D., Ph.D. (Mary’s Hospital, The Catholic University of Korea)
Location: Georgia World Congress Center, Hall B1-B2
 

PACE Trial: Molecular Response Data

 
Title: Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3763
Author: Andreas Hochhaus, M.D., University Medical Center Jena in Germany
Location: Georgia World Congress Center, Hall B1-B2
 

PACE Trial: Multivariate Analysis of Parameters

 
Title: Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3747
Presenter: Michael Mauro, M.D. (Oregon Health & Science University)
Location: Georgia World Congress Center, Hall B1-B2
 

Phase 1 Trial: Long-term Results

 
Title: Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3743
Presenter: Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute)
Location: Georgia World Congress Center, Hall B1-B2
 

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter ( @ARIADPharm).



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,390.52 +195.10 1.13%
S&P 500 2,018.05 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs